From Pathogenesis, Epidemiology, and Genetics to Definitions, Diagnosis, and Treatments of Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013

Journal of Investigative Dermatology

Volumn 135, Issue 1, 2015, Pages 7-12

  Schultz, Heather Y ^a   Dutz, Jan P ^b   Furukawa, Fukumi ^c   Goodfield, Mark J ^d   Kuhn, Annegret ^e   Lee, Lela A ^f   Nyberg, Filippa ^g   Szepietowski, Jacek C ^h   Sontheimer, Richard D ⁱ   Werth, Victoria P ^j,k  

^a Medical Writer   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g DANDERYD HOSPITAL   (Sweden)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j Perelman Center for Advanced Medicine   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA DEFENSIN 2; BETA DEFENSIN 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHLOROQUINE; DAPSONE; ETRETINATE; HYDROXYCHLOROQUINE; ISOTRETINOIN; METHOTREXATE; PSORIASIN; SUNSCREEN; TACROLIMUS; TOLL LIKE RECEPTOR 7; VITAMIN D;

CONFERENCE PAPER; DERMATOMYOSITIS; GENETIC ASSOCIATION; GENETICS; HUMAN; INCIDENCE; LOSS OF FUNCTION MUTATION; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION; CONSENSUS; DERMATOLOGY; LUPUS ERYTHEMATOSUS, CUTANEOUS; TRENDS;

CONSENSUS; DERMATOLOGY; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS;

EID: 84925227810     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.316     Document Type: Conference Paper

References (37)

1. Bartlett SJ, Hewlett S, Bingham CO 3rd et al. (2013) Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 71:1855-60
2. Bendewald MJ, Wetter DA, Li X et al. (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a populationbased study in Olmsted County, Minnesota. Arch Dermatol 146:26-30
3. Biazar C, Sigges J, Patsinakidis N et al. (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444-54
4. Casciola-Rosen L, Nagaraju K, Plotz P et al. (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201:591-601
5. Chren MM, Lasek RJ, Flocke SA et al. (1997a) Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433-40
6. Chren MM, Lasek RJ, Quinn LM et al. (1997b) Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 108:103-7
7. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993-2000
8. Dalkey N, Helmer O (1963) An experimental application of the Delphi method to the use of experts. Management Science 9:458-67
9. Durosaro O, Davis MD, Reed KB et al. (2009) Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 145:249-53
10. Fiorentino DF, Chung LS, Christopher-Stine L et al. (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65:2954-62
11. Frances C, Cosnes A, Duhaut P et al. (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148:479-84
12. Goreshi R, Chock M, Foering K et al. (2011) Quality of life in dermatomyositis. J Am Acad Dermatol 65:1107-16
13. Gottfried I, Seeber A, Anegg B et al. (2000) High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29-35
14. Gronhagen CM, Fored CM, Granath F et al. (2011) Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 164:1335-41
15. Gronhagen CM, Fored CM, Linder M et al. (2012) Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 167:296-305
16. Harder J, Schroder JM, Glaser R (2013) The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol 22:1-5
17. Hsu CC, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res & Evaluation 12:1-8
18. Jallouli M, Frances C, Piette JC et al. (2013) Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a casecontrol study. JAMA Dermatol 149:935-40
19. Jessop S, Whitelaw DA, Delamere FM (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 4:CD002
20. Kreuter A, Jaouhar M, Skrygan M et al. (2011) Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J Am Acad Dermatol 65:125-33
21. Kuhn A, Gensch K, Haust M et al. (2011) Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 65:54-64. e1-2
22. Kuhn A, Kuehn E, Meuth AM et al. (2009) Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 8:702-12
23. Kuhn A, Lehmann P (2004) Classification of Cutaneous Lupus Erythematosus. Springer-Verlag: Berlin
24. Li QZ, Karp DR, Quan J et al. (2011) Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 13:R38
25. Mammen AL, Casciola-Rosen LA, Hall JC et al. (2009) Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 60:3784-93
26. Morganroth PA, Kreider ME, Okawa J et al. (2010) Interstitial lung disease in classic and clinically amyopathic dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 146:729-38
27. O'Brien BA, Geng X, Orteu CH et al. (2006) A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J Autoimmun 26:104-5
28. Oddis CV, Reed AM, Aggarwal R et al. (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314-24
29. Okiyama N, Sugihara T, Iwakura Y et al. (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60:2505-12
30. Renne J, Werfel T, Wittmann M (2008) High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus [corrected]. Br J Dermatol 159:485-6
31. Sigges J, Biazar C, Landmann A et al. (2013) Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) core set questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 12: 694-702
32. Sugihara T, Sekine C, Nakae T et al. (2007) A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum 56:1304-4
33. Terrier B, Derian N, Schoindre Y et al. (2012) Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 14:R221
34. Tsai WW, Wang Z, Yiu TT et al. (2010) TRIM2 links a non-canonical histone signature to breast cancer. Nature 468:927-32
35. Verma SM, Okawa J, Propert KJ et al. (2014) The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol 170:315-21
36. Yokoe T, Toiyama Y, Okugawa Y et al. (2010) KAP1 is associated with peritoneal carcinomatosis in gastric cancer. Ann Surg Oncol 17:821-8
37. Yokogawa M, Takaishi M, Nakajima K et al. (2014) Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus. Arthritis Rheumatol 66:694-706